Cargando…

Skin disorder management in oral anticancer drugs by collaboration of hospital pharmacists and community pharmacists

BACKGROUND: In Japan, the multidisciplinary team approach in cancer chemotherapy has become quite widespread. However, patients treated with oral anticancer drugs in outpatient clinics usually receive short medical examinations from doctors without any intervention of pharmacists. To improve this me...

Descripción completa

Detalles Bibliográficos
Autores principales: Urakawa, Ryuta, Hashimoto, Sanae, Hirohata, Hideki, Sakai, Katsunori, Matsuura, Kayo, Ito, Yumiko, Tarutani, Masahito, Kubota, Kazumi, Ueda, Mikiko, Uejima, Etsuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163684/
https://www.ncbi.nlm.nih.gov/pubmed/33161506
http://dx.doi.org/10.1007/s00520-020-05875-2
_version_ 1783700954131988480
author Urakawa, Ryuta
Hashimoto, Sanae
Hirohata, Hideki
Sakai, Katsunori
Matsuura, Kayo
Ito, Yumiko
Tarutani, Masahito
Kubota, Kazumi
Ueda, Mikiko
Uejima, Etsuko
author_facet Urakawa, Ryuta
Hashimoto, Sanae
Hirohata, Hideki
Sakai, Katsunori
Matsuura, Kayo
Ito, Yumiko
Tarutani, Masahito
Kubota, Kazumi
Ueda, Mikiko
Uejima, Etsuko
author_sort Urakawa, Ryuta
collection PubMed
description BACKGROUND: In Japan, the multidisciplinary team approach in cancer chemotherapy has become quite widespread. However, patients treated with oral anticancer drugs in outpatient clinics usually receive short medical examinations from doctors without any intervention of pharmacists. To improve this medical circumstance, we made a skin disorder manual for community pharmacists and evaluated its feasibility. METHODS: Patients who underwent oral skin toxic chemotherapy from May 1, 2017, to October 31, 2017, were enrolled. The severity of skin toxicities was evaluated based on NCI-CTCAE ver4.0. Skin care and skin disorders were assessed by community pharmacists based on the assessment document arranged by the investigator. Numbers of patients who replied to the assessment, numbers of replies, numbers of assessments and instructions for skin care, and numbers of prescription proposals were evaluated to assess the value of intervention of community pharmacists. RESULTS: Sixty-two patients were enrolled in this study. Community pharmacy responded to 55 patients (88.7%), for a total of 335 replies. The data described in the replies were as follows: 317 assessments of skin disorders (94.6%), 307 assessments of skin care (91.6%), 248 instructions for skin care (74%), and 19 prescription proposals (5.7%). CONCLUSIONS: Community pharmacists have high motivation for prevention and early detection of skin disorders. Although the number of prescription proposals is small, some proposals have contributed to improving side effects. Collaboration of hospital pharmacists and community pharmacists is important for prevention, early detection, and treatment of skin disorders caused by oral anticancer drugs.
format Online
Article
Text
id pubmed-8163684
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-81636842021-06-17 Skin disorder management in oral anticancer drugs by collaboration of hospital pharmacists and community pharmacists Urakawa, Ryuta Hashimoto, Sanae Hirohata, Hideki Sakai, Katsunori Matsuura, Kayo Ito, Yumiko Tarutani, Masahito Kubota, Kazumi Ueda, Mikiko Uejima, Etsuko Support Care Cancer Original Article BACKGROUND: In Japan, the multidisciplinary team approach in cancer chemotherapy has become quite widespread. However, patients treated with oral anticancer drugs in outpatient clinics usually receive short medical examinations from doctors without any intervention of pharmacists. To improve this medical circumstance, we made a skin disorder manual for community pharmacists and evaluated its feasibility. METHODS: Patients who underwent oral skin toxic chemotherapy from May 1, 2017, to October 31, 2017, were enrolled. The severity of skin toxicities was evaluated based on NCI-CTCAE ver4.0. Skin care and skin disorders were assessed by community pharmacists based on the assessment document arranged by the investigator. Numbers of patients who replied to the assessment, numbers of replies, numbers of assessments and instructions for skin care, and numbers of prescription proposals were evaluated to assess the value of intervention of community pharmacists. RESULTS: Sixty-two patients were enrolled in this study. Community pharmacy responded to 55 patients (88.7%), for a total of 335 replies. The data described in the replies were as follows: 317 assessments of skin disorders (94.6%), 307 assessments of skin care (91.6%), 248 instructions for skin care (74%), and 19 prescription proposals (5.7%). CONCLUSIONS: Community pharmacists have high motivation for prevention and early detection of skin disorders. Although the number of prescription proposals is small, some proposals have contributed to improving side effects. Collaboration of hospital pharmacists and community pharmacists is important for prevention, early detection, and treatment of skin disorders caused by oral anticancer drugs. Springer Berlin Heidelberg 2020-11-07 2021 /pmc/articles/PMC8163684/ /pubmed/33161506 http://dx.doi.org/10.1007/s00520-020-05875-2 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Urakawa, Ryuta
Hashimoto, Sanae
Hirohata, Hideki
Sakai, Katsunori
Matsuura, Kayo
Ito, Yumiko
Tarutani, Masahito
Kubota, Kazumi
Ueda, Mikiko
Uejima, Etsuko
Skin disorder management in oral anticancer drugs by collaboration of hospital pharmacists and community pharmacists
title Skin disorder management in oral anticancer drugs by collaboration of hospital pharmacists and community pharmacists
title_full Skin disorder management in oral anticancer drugs by collaboration of hospital pharmacists and community pharmacists
title_fullStr Skin disorder management in oral anticancer drugs by collaboration of hospital pharmacists and community pharmacists
title_full_unstemmed Skin disorder management in oral anticancer drugs by collaboration of hospital pharmacists and community pharmacists
title_short Skin disorder management in oral anticancer drugs by collaboration of hospital pharmacists and community pharmacists
title_sort skin disorder management in oral anticancer drugs by collaboration of hospital pharmacists and community pharmacists
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163684/
https://www.ncbi.nlm.nih.gov/pubmed/33161506
http://dx.doi.org/10.1007/s00520-020-05875-2
work_keys_str_mv AT urakawaryuta skindisordermanagementinoralanticancerdrugsbycollaborationofhospitalpharmacistsandcommunitypharmacists
AT hashimotosanae skindisordermanagementinoralanticancerdrugsbycollaborationofhospitalpharmacistsandcommunitypharmacists
AT hirohatahideki skindisordermanagementinoralanticancerdrugsbycollaborationofhospitalpharmacistsandcommunitypharmacists
AT sakaikatsunori skindisordermanagementinoralanticancerdrugsbycollaborationofhospitalpharmacistsandcommunitypharmacists
AT matsuurakayo skindisordermanagementinoralanticancerdrugsbycollaborationofhospitalpharmacistsandcommunitypharmacists
AT itoyumiko skindisordermanagementinoralanticancerdrugsbycollaborationofhospitalpharmacistsandcommunitypharmacists
AT tarutanimasahito skindisordermanagementinoralanticancerdrugsbycollaborationofhospitalpharmacistsandcommunitypharmacists
AT kubotakazumi skindisordermanagementinoralanticancerdrugsbycollaborationofhospitalpharmacistsandcommunitypharmacists
AT uedamikiko skindisordermanagementinoralanticancerdrugsbycollaborationofhospitalpharmacistsandcommunitypharmacists
AT uejimaetsuko skindisordermanagementinoralanticancerdrugsbycollaborationofhospitalpharmacistsandcommunitypharmacists